198 related articles for article (PubMed ID: 34209209)
1. Ancillary Diagnostic Investigations in Malignant Pleural Mesothelioma.
Dipper A; Maskell N; Bibby A
Cancers (Basel); 2021 Jun; 13(13):. PubMed ID: 34209209
[TBL] [Abstract][Full Text] [Related]
2. Use of p16 FISH for differential diagnosis of mesothelioma in smear preparations.
Nabeshima K; Matsumoto S; Hamasaki M; Hida T; Kamei T; Hiroshima K; Tsujimura T; Kawahara K
Diagn Cytopathol; 2016 Sep; 44(9):774-80. PubMed ID: 27219841
[TBL] [Abstract][Full Text] [Related]
3. A diagnosis of malignant pleural mesothelioma can be made by effusion cytology: results of a 20 year audit.
Segal A; Sterrett GF; Frost FA; Shilkin KB; Olsen NJ; Musk AW; Nowak AK; Robinson BW; Creaney J
Pathology; 2013 Jan; 45(1):44-8. PubMed ID: 23222247
[TBL] [Abstract][Full Text] [Related]
4. Pleural fluid cytological yield and visceral pleural invasion in patients with epithelioid malignant pleural mesothelioma.
Pinelli V; Laroumagne S; Sakr L; Marchetti GP; Tassi GF; Astoul P
J Thorac Oncol; 2012 Mar; 7(3):595-8. PubMed ID: 22307010
[TBL] [Abstract][Full Text] [Related]
5. Advances in pathological diagnosis of mesothelioma: what pulmonologists should know.
Louw A; Badiei A; Creaney J; Chai MS; Lee YCG
Curr Opin Pulm Med; 2019 Jul; 25(4):354-361. PubMed ID: 31169558
[TBL] [Abstract][Full Text] [Related]
6. Mesothelin in serum and pleural effusion in the diagnosis of malignant pleural mesothelioma with non-positive cytology.
Franceschini MC; Ferro P; Canessa PA; Battolla E; Dessanti P; Valentino A; Casolari L; Fontana V; Pezzi R; Fedeli F; Pistillo MP; Roncella S
Anticancer Res; 2014 Dec; 34(12):7425-9. PubMed ID: 25503183
[TBL] [Abstract][Full Text] [Related]
7. Genomic-based ancillary assays offer improved diagnostic yield of effusion cytology with potential challenges in malignant pleural mesothelioma.
Kinoshita Y; Hamasaki M; Matsumoto S; Yoshimura M; Sato A; Tsujimura T; Kamei T; Kawahara K; Nabeshima K
Pathol Int; 2020 Sep; 70(9):671-679. PubMed ID: 32542810
[TBL] [Abstract][Full Text] [Related]
8. Deletion status of p16 in effusion smear preparation correlates with that of underlying malignant pleural mesothelioma tissue.
Hida T; Matsumoto S; Hamasaki M; Kawahara K; Tsujimura T; Hiroshima K; Kamei T; Taguchi K; Iwasaki A; Oda Y; Honda H; Nabeshima K
Cancer Sci; 2015 Nov; 106(11):1635-41. PubMed ID: 26291840
[TBL] [Abstract][Full Text] [Related]
9. Molecular markers and new diagnostic methods to differentiate malignant from benign mesothelial pleural proliferations: a literature review.
Bruno R; Alì G; Fontanini G
J Thorac Dis; 2018 Jan; 10(Suppl 2):S342-S352. PubMed ID: 29507804
[TBL] [Abstract][Full Text] [Related]
10. Detection of TGF-β in pleural effusions for diagnosis and prognostic stratification of malignant pleural mesothelioma.
Stockhammer P; Ploenes T; Theegarten D; Schuler M; Maier S; Aigner C; Hegedus B
Lung Cancer; 2020 Jan; 139():124-132. PubMed ID: 31778960
[TBL] [Abstract][Full Text] [Related]
11. Malignant pleural mesothelioma and mesothelial hyperplasia: A new molecular tool for the differential diagnosis.
Bruno R; Alì G; Giannini R; Proietti A; Lucchi M; Chella A; Melfi F; Mussi A; Fontanini G
Oncotarget; 2017 Jan; 8(2):2758-2770. PubMed ID: 27835874
[TBL] [Abstract][Full Text] [Related]
12. Multiplex Soluble Biomarker Analysis from Pleural Effusion.
Javadi J; Dobra K; Hjerpe A
Biomolecules; 2020 Jul; 10(8):. PubMed ID: 32731396
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic efficacy of electron microscopy and pleural effusion cytology for the distinction of pleural mesothelioma and lung adenocarcinoma.
Domínguez-Malagón H; Cano-Valdez AM; González-Carrillo C; Campos-Salgado YE; Lara-Garcia A; Lopez-Mejia M; Corona-Cruz JF; Arrieta O
Ultrastruct Pathol; 2016; 40(5):254-60. PubMed ID: 27405014
[TBL] [Abstract][Full Text] [Related]
14. miR-130A as a diagnostic marker to differentiate malignant mesothelioma from lung adenocarcinoma in pleural effusion cytology.
Cappellesso R; Galasso M; Nicolè L; Dabrilli P; Volinia S; Fassina A
Cancer Cytopathol; 2017 Aug; 125(8):635-643. PubMed ID: 28449331
[TBL] [Abstract][Full Text] [Related]
15. Malignant pleural mesothelioma: diagnostic value of medical thoracoscopy and long-term prognostic analysis.
Xu LL; Yang Y; Wang Z; Wang XJ; Tong ZH; Shi HZ
BMC Pulm Med; 2018 Apr; 18(1):56. PubMed ID: 29615010
[TBL] [Abstract][Full Text] [Related]
16. CD44 and its ligand hyaluronan as potential biomarkers in malignant pleural mesothelioma: evidence and perspectives.
Cortes-Dericks L; Schmid RA
Respir Res; 2017 Apr; 18(1):58. PubMed ID: 28403901
[TBL] [Abstract][Full Text] [Related]
17. Pleural effusion biomarkers and computed tomography findings in diagnosing malignant pleural mesothelioma: A retrospective study in a single center.
Otoshi T; Kataoka Y; Ikegaki S; Saito E; Matsumoto H; Kaku S; Shimada M; Hirabayashi M
PLoS One; 2017; 12(10):e0185850. PubMed ID: 28968445
[TBL] [Abstract][Full Text] [Related]
18. The established and future biomarkers of malignant pleural mesothelioma.
Panou V; Vyberg M; Weinreich UM; Meristoudis C; Falkmer UG; Røe OD
Cancer Treat Rev; 2015 Jun; 41(6):486-95. PubMed ID: 25979846
[TBL] [Abstract][Full Text] [Related]
19. Improved diagnosis and prognostication of patients with pleural malignant mesothelioma using biomarkers in pleural effusions and peripheral blood samples - a short report.
Beije N; Kraan J; den Bakker MA; Maat APWM; van der Leest C; Cornelissen R; Van NM; Martens JWM; Aerts JGJV; Sleijfer S
Cell Oncol (Dordr); 2017 Oct; 40(5):511-519. PubMed ID: 28577209
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic yield of pleural fluid cytology in malignant effusions: an Australian tertiary centre experience.
Loveland P; Christie M; Hammerschlag G; Irving L; Steinfort D
Intern Med J; 2018 Nov; 48(11):1318-1324. PubMed ID: 29869427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]